LABORATORY EXAMINATION OF HEMOLYTIC DISEASE IN NEONATES DUE TO RHESUS INCOMPATIBILITY

By
Danny Ernest Jonas Luhulima[1], Christian Ronald Tanggo[2], Ria Amelia[3]
[1.2] Faculty of Medicine, Universitas Kristen Indonesia, Jakarta, Indonesia
[3] Sekolah Tinggi Ilmu Kesehatan Mitra Keluarga, Bekasi, Indonesia
E-mail: [1]danny.luhulima@uki.ac.id, [2]christian.tanggo@uki.ac.id,
[3]ria.amelia@stikesmitrakeluarga.ac.id

Abstract: *Hemolytic disease of the newborn (HDN) occurs when fetal red blood cells (RBCs), which possess an antigen that the mother lacks, cross the placenta into the maternal circulation, where they stimulate antibody production. The antibodies return to the fetal circulation and result in RBC destruction. Three classifications of HDN are: ABO, other causes like unexpected immune antibodies like anti-c or anti-K and Rhesus–anti D alone or may be accompanied by other Rh antibodies, examples anti-D with anti-C or anti-E. Clinical presentation of HDN varies from mild jaundice and anemia to hydrops fetalis (with ascites, pleural and pericardial effusions). This article discusses hemolytic due to incompability Rhesus anti-D.)*

INTRODUCTION

Hemolytic disease of the newborn (HDN) is a hematologic disorder caused by immunologic destruction of fetal or neonatal erythrocytes. One of the most important causes is Rhesus incompatibility, which occurs when fetal erythrocytes carrying the D antigen enter the circulation of an Rh-negative mother and trigger the formation of IgG antibodies. These antibodies then cross the placenta back to the fetus, leading to hemolysis that may result in severe anemia, jaundice, hydrops fetalis, and perinatal death.

Although anti-D prophylaxis has reduced the incidence of severe HDN in many developed countries, HDN due to Rhesus incompatibility remains a significant problem in numerous developing settings because of limited antenatal screening, inadequate monitoring of high-risk pregnancies, and variable access to laboratory facilities. Key issues include unrecognized alloimmunization, inconsistent interpretation of laboratory findings, and delayed management of hyperbilirubinemia and anemia in affected neonates.

Previous studies and reviews have largely focused on the pathogenesis, clinical course, preventive strategies with immunoprophylaxis, and transfusion management in HDN. However, a concise and integrated discussion of the role and algorithm of laboratory investigations in HDN specifically due to Rhesus incompatibility, particularly anti-D, is still relatively limited. In fact, tests such as blood group and Rhesus typing, antibody screening and identification, antiglobulin tests, and assessment of hemoglobin, reticulocytes, and

bilirubin levels are critical for diagnosis, monitoring, and therapeutic decision-making.

Based on this background, this literature review aims to provide a concise yet systematic overview of the role of laboratory examinations in hemolytic disease of the newborn caused by Rhesus incompatibility. It is expected that this review will offer practical guidance for clinicians and laboratory personnel in early detection, assessment of disease severity, and planning of more rational management in Rhesus-related HDN.

LITERATURE REVIEW

Hemolytic disease of the newborn (HDN) is an immune-mediated hemolytic anemia caused by maternal IgG antibodies directed against fetal red blood cell (RBC) antigens that cross the placenta and induce RBC destruction. Clinically, HDN presents with anemia and jaundice of varying severity and, in severe cases, may progress to *hydrops fetalis* and perinatal death.

Rhesus incompatibility, particularly anti-D alloimmunization, is the most important cause of severe HDN. In Rh-negative mothers exposed to Rh-positive fetal RBCs, fetomaternal hemorrhage can trigger formation of anti-D antibodies. In subsequent pregnancies, these IgG antibodies cross the placenta, bind to fetal Rh-positive RBCs, and cause progressive hemolysis, anemia, tissue hypoxia, and compensatory extramedullary hematopoiesis. If untreated, this cascade leads to *hydrops fetalis* in utero, and after birth to severe hyperbilirubinemia with risk of *kernicterus* and long-term neurologic sequelae.

Prevention of Rh-mediated HDN is theoretically based on avoiding maternal sensitization through administration of Rhesus immune globulin (RhIg) to Rh-negative mothers after significant fetomaternal hemorrhage and around delivery of an Rh-positive infant. From a diagnostic perspective, the theoretical basis of key tests includes ABO and Rh typing, antibody screening and identification (indirect antiglobulin test), serial anti-D titers, and the direct antiglobulin test in the neonate, complemented by hemoglobin, reticulocyte count, and bilirubin measurements to assess the degree of hemolysis. This immunohematologic framework underlies the development of rational laboratory algorithms for early detection, monitoring, and optimal management of HDN due to Rhesus incompatibility.

RESEARCH METHOD
Type and Design of Study

This paper uses a narrative literature review design that focuses on the role of laboratory examinations in hemolytic disease in neonates due to Rhesus anti-D incompatibility. The review is organized systematically, starting from literature searching, selection of relevant articles, data extraction, and finally narrative synthesis to answer the issues raised in the introduction and theoretical framework.

Data Sources

The data used are secondary data obtained from indexed international and national scientific journals (such as PubMed, ScienceDirect, Scopus, and Google Scholar), textbooks in clinical pathology, blood transfusion, hematology, and neonatology, as well as clinical practice guidelines and professional organization guidelines, for example guidelines on the management of hyperbilirubinemia and the prevention of Rh.

Search and Selection Procedure

The literature search was conducted using Indonesian and English keywords, for example:

"hemolytic disease of the newborn", "Rh incompatibility", "Rhesus anti-D", "laboratory tests in HDN", "penyakit hemolisis pada neonatus", and "pemeriksaan laboratorium HDN", combined with Boolean operators (AND, OR). Titles and abstracts were screened to assess relevance; articles that passed this stage were then selected further through full-text review, and only literature that met the criteria was included in the discussion.

Data Analysis and Presentation

The analysis was carried out descriptively using qualitative content analysis. [8, 9] To facilitate reading and drawing conclusions, important information from the selected literature was first grouped into several main themes, namely:

1. pathogenesis and immune mechanisms of HDN,
2. laboratory examinations in the mother (antibody screening and identification, anti-D titer),
3. laboratory examinations in the fetus and neonate (DAT, hemoglobin, reticulocyte count, bilirubin),
4. implications of examination results for clinical decision-making and prevention.

Each theme was then analyzed in depth to explore the interrelationships between concepts and their relevance to the objectives of the literature review. The results of the analysis were synthesized into a structured narrative in the Results and Discussion section, and subsequently summarized briefly and systematically in the Conclusion and Recommendations (future works) section.

RESULTS AND DISCUSSION

Synthesis of Literature Findings

Based on the literature review, the analyzed articles generally show that hemolytic disease in neonates due to Rhesus incompatibility remains a clinically relevant problem, especially in countries where anti-D prophylaxis coverage is not yet uniform. A consistent pattern that emerges is: (1) the central role of Rhesus anti-D alloimmunization in triggering fetal erythrocyte hemolysis; (2) the importance of stepwise screening and laboratory monitoring in the mother, fetus, and neonate; and (3) a clear relationship between laboratory findings and clinical decision-making, ranging from antenatal monitoring to postnatal interventions.

Pathogenesis and Implications for Laboratory Testing

The literature describes that hemolysis begins when maternal IgG antibodies cross the placenta and bind to fetal erythrocytes carrying the D antigen. These antigen–antibody complexes are then phagocytosed by the reticuloendothelial system, causing progressive anemia and hyperbilirubinemia. Understanding this pathogenesis forms the basis for selecting laboratory parameters that focus on: (1) detection of maternal antibodies, (2) evidence of immune hemolysis on the surface of fetal/neonatal erythrocytes, and (3) the degree of anemia and bilirubin burden. Thus, each laboratory result does not stand alone, but is interpreted within the context of the immunologic cascade underlying HDN.

Laboratory Examinations in the Mother

The review shows that the initial mandatory examinations are determination of maternal and paternal ABO and Rhesus blood groups, followed by maternal antibody screening using the indirect antiglobulin test. In Rh-negative mothers, the presence and rising titer of anti-D antibodies are indicators of the risk of fetal hemolysis. Several studies

....

ISSN 2798-3471 (Cetak)   **Journal of Innovation Research and Knowledge**
ISSN 2798-3641 (Online)

emphasize that the "critical" titer threshold may vary between centers, but a consistent upward trend in titers is generally associated with an increased risk of fetal anemia. In addition, specific tests to detect fetomaternal hemorrhage (such as the Kleihauer–Betke test) are used to determine the extent of fetal erythrocyte exposure and the required dose of anti-D immunoglobulin.

In practical terms, maternal laboratory examinations provide two main benefits: (1) early identification of pregnancies at high risk for HDN, and (2) determination of the need for intensive fetal monitoring or prophylactic intervention. In healthcare settings with limited resources, the literature highlights the importance of at least performing Rhesus typing and antibody screening at the initial antenatal visit.

Laboratory Examinations in the Fetus and Neonate

At the fetal level, some sources explain that the degree of anemia can be estimated indirectly through clinical and ancillary assessments (such as middle cerebral artery Doppler), although from a laboratory standpoint the main focus remains on postnatal evaluation. After birth, the most frequently recommended panel of examinations includes:
1. determination of the infant's ABO and Rhesus blood group,
2. direct antiglobulin test (DAT),
3. hemoglobin/hematocrit and reticulocyte count,
4. total bilirubin and its fractions.

A positive DAT in an infant with anemia and hyperbilirubinemia supports the diagnosis of immune hemolytic anemia. Low hemoglobin levels with elevated reticulocytes indicate active hemolysis accompanied by a compensatory bone marrow response. A rapidly rising bilirubin level within the first 24–48 hours is an indicator of kernicterus risk and serves as the basis for determining the need for intensive phototherapy or exchange transfusion.

Summary of the Role of Laboratory Examinations

To summarize the literature findings on the role of laboratory examinations in HDN due to Rhesus incompatibility, Table 1 is prepared to illustrate the relationship between each type of test and its main clinical implications.

Table 1. Summary of the main laboratory examinations in HDN due to Rhesus incompatibility

Type of Examination	Subject	Main Objective	Main Clinical Implication
ABO and Rhesus blood group	Mother, father, infant	Identification of potential incompatibility	Determining HDN risk and the need for further monitoring
Antibody screening & identification (IAT)	Mother	Detection and characterization of alloantibodies	Establishing the pregnancy as high risk for HDN
Anti-D antibody titer	Mother	Assessing the degree of sensitization	Determining the intensity of fetal monitoring
Direct antiglobulin test (DAT)	Infant	Detection of antibodies/complement on infant RBCs	Confirming immune hemolysis in the neonate
Hemoglobin/hematocrit & reticulocyte count	Infant	Assessing the degree of anemia and erythropoietic response	Determining the need for transfusion and monitoring of anemia
Total and fractionated bilirubin	Infant	Assessing the degree of hyperbilirubinemia	Determining indications for phototherapy and

			exchange transfusion
Fetomaternal hemorrhage test (e.g., K–B test)	Mother	Measuring the amount of fetal erythrocytes in maternal circulation	Calculating the required dose of post-partum anti-D immunoglobulin

Source: Processed from various literature.

The table shows that each laboratory examination has a complementary role, ranging from risk identification and diagnostic confirmation to therapeutic decision-making. By integrating information from these various parameters, clinicians can formulate a more precise, individualized management strategy for both mother and infant.

Clinical Discussion and Practical Implications

Overall, the literature review confirms that a systematic laboratory approach is crucial for the successful management of HDN due to Rhesus incompatibility. At the maternal level, Rhesus typing and antibody screening enable prevention through timely administration of anti-D immunoglobulin. At the neonatal level, integrated interpretation of DAT, hemoglobin, reticulocyte count, and bilirubin provides a strong basis for determining the need for intensive phototherapy, exchange transfusion, and further monitoring.

The literature also highlights several challenges in implementation, including limited laboratory facilities, variability in testing protocols, and suboptimal integration between antenatal and perinatal services. Therefore, one of the key practical implications of these findings is the need to develop clear and simple laboratory algorithms that can be adapted to local resource settings, so that the principles recommended in the literature can be applied more broadly and consistently in daily clinical practice.

CONCLUSION

Based on this literature review, it can be concluded that hemolytic disease in neonates due to Rhesus incompatibility is primarily rooted in anti-D alloimmunization in Rh-negative mothers. The sequence of immunological events—from the entry of fetal erythrocytes into the maternal circulation to the occurrence of hemolysis in the fetus and infant—shows that accurate, targeted laboratory testing initiated during the antenatal period plays a key role in the prevention, early detection, and management of HDN. Thus, strengthening theoretical understanding of pathogenesis and interpretation of laboratory results becomes an essential foundation for improving the quality of maternal and neonatal health services.

As a follow-up, several recommendations can be proposed: the development of simple and standardized laboratory algorithms, enhancement of education and training for health workers regarding the risks of Rhesus incompatibility and the interpretation of test results, and the implementation of community outreach programs that emphasize the importance of antenatal visits, blood group and Rhesus typing, and adherence to anti-D prophylaxis. These recommendations also serve as directions for further research and development (future works) so that efforts to prevent and manage HDN can be carried out more effectively and sustainably.

REFERENCES

[1] American Academy of Pediatrics Subcommittee on Hyperbilirubinemia. (2004). Management of hyperbilirubinemia in the newborn infant 35 or more weeks of gestation. *Pediatrics*, *114*(1), 297-316.

[2] De Haas, M., Thurik, F. F., Koelewijn, J. M., & van der Schoot, C. E. (2015). Haemolytic disease of the fetus and newborn. *Vox sanguinis*, *109*(2), 99-113.

[3] Delaney, M., & Matthews, D. C. (2015). Hemolytic disease of the fetus and newborn: managing the mother, fetus, and newborn. *Hematology 2014, the American Society of Hematology Education Program Book*, *2015*(1), 146-151.

[4] Fasano, R. M. (2016, February). Hemolytic disease of the fetus and newborn in the molecular era. In *Seminars in Fetal and Neonatal Medicine* (Vol. 21, No. 1, pp. 28-34). WB Saunders.

[5] Luhulima, D. E. J. (2021). Pemeriksaan Laboratorium Penyakit Hemolisis pada Neonatus Akibat Inkompatibilitas Rhesus.

[6] Melanie SK, Hemolytic disease of the newborn and fetus; Chapter 20; in Harmening DM (eds); Modern blood blanking and transfusion practices; Fourth edition; Bangkok Thailand; Book promotion and service Co. LTD; 1994; 421–433.

[7] Nadeak, B., Manik, J., & Destine, D. (2025). The Effectiveness of Managerial Approaches in Promoting Adolescent Healthy Lifestyles: A Qualitative Study at HKBP Gedong Church. Asian Journal of Basic Science & Research, 7(2), 119-128.

[8] Santavy, J. (2010). Hemolytic disease in the newborn–history and prevention in the World and the Czech Republic. *Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub*, *154*(2), 147-151.

[9] Sheth, S. "Hemolytic Diseases of the Newborn." Dalam *Neonatology*, disunting oleh Richard A. Polin dan John M. Lorenz, 401–404. Cambridge: Cambridge University Press, 2008. https://doi.org/10.1017/CBO9780511547270.039

[10] Wibowo, H., S. Nurrahmah, dan R.S.E. Gantini. "Maternal IgG in Hemolytic Disease of the Fetus and Newborn–ABO Incompatibility." *Medical Journal of Indonesia* 33, no. 2 (2024): 70–74.